TSW
SOPH icon

Thompson Siegel & Walmsley’s SOPHiA GENETICS SOPH Stock Holding History

Thompson Siegel & Walmsley’s Portfolio SOPH Stock Details SOPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-29,780
Closed -$142K – 426
2025
Q3 		$142K Buy
+29,780
New +$102K ﹤0.01% 404

Other funds holding SOPH

GIM
Generation Investment Management London, United Kingdom $11.2B AUM 0.58% 1-Year Est. Return
ACM
AKRE Capital Management Middleburg, Virginia $6.13B AUM 15.27% 1-Year Est. Return
BPC
Banque Pictet & Cie Geneva 73, Switzerland $16B AUM 29.1% 1-Year Est. Return
AWA
Alta Wealth Advisors Woburn, Massachusetts $308M AUM 27.87% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return
ACM
Archon Capital Management Seattle, Washington $177M AUM 108.05% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
BPCE
Bank Pictet & Cie (Europe) Frankfurt Am Main, Germany $5.12B AUM 27.39% 1-Year Est. Return
1CM
1492 Capital Management Milwaukee, Wisconsin $263M AUM 61.9% 1-Year Est. Return
EDRH
Edmond de Rothschild Holding Chambesy, Switzerland $6.91B AUM 19.7% 1-Year Est. Return

Thompson Siegel & Walmsley's SOPH Position: Q4 2025 in Review

Thompson Siegel & Walmsley sold out of SOPHiA GENETICS (SOPH) in Q4 2025, closing a stake of 29,780 shares — an estimated $142K sold.

Thompson Siegel & Walmsley first reported a position in SOPH in Q3 2025 and held it in 1 quarter. The position peaked at $142K in Q3 2025. 42 funds tracked by Wall St. Rank hold SOPH as of Q4 2025.

  • Thompson Siegel & Walmsley reported no remaining SOPHiA GENETICS position as of Q4 2025 after selling out during the quarter.
  • Thompson Siegel & Walmsley sold 29,780 SOPHiA GENETICS shares in Q4 2025, an estimated $142K.
  • Thompson Siegel & Walmsley first reported a position in SOPHiA GENETICS in Q3 2025 and held it in 1 quarter.
  • Thompson Siegel & Walmsley's SOPHiA GENETICS position peaked at $142K in Q3 2025.
  • 42 funds tracked by Wall St. Rank held SOPHiA GENETICS as of Q4 2025.

Based on Thompson Siegel & Walmsley's 13F filing for Q4 2025, filed 10 Feb 2026.